Background: Psoriasis, a chronic, immune-mediated, inflammatory disease, affects 2‒3% of the population. Tyrosine kinase 2 (TYK2) mediates cytokine signaling involved in adaptive [interleukin (IL)-12, IL-23] and innate (type-I interferons) immune responses; IL-23-driven T-helper (Th)17 pathways play a key role in chronic inflammation in psoriasis. In a phase 2 trial, deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, reduced IL-23/Th17 and type-I interferon pathway expression in the skin of patients with moderate to severe plaque psoriasis, reductions that were accompanied by clinical improvement of psoriatic lesions.
Objectives: The aim of this study was to identify biomarkers of psoriatic disease in serum from patients enrolled in the phase 2 trial and to assess the effects of deucravacitinib on those biomarkers.
Methods: Serum biomarkers from Olink proteomics and other quantitative assays were evaluated for a pharmacodynamic response to deucravacitinib treatment and correlation with psoriasis disease activity measures.
Results: Serum biomarkers associated with the IL-23/Th17 pathway [IL-17A, IL-17C, IL-19, IL-20, beta-defensin, and peptidase inhibitor 3 (PI3)] were upregulated in patients with psoriasis versus healthy controls. Deucravacitinib treatment reduced IL-17A (adjusted mean change from baseline at Day 85; 12 mg once daily versus placebo; -0.240 versus -0.067), IL-17C (-14.850 versus -1.664), IL-19 (-96.445 versus -8.119), IL-20 (-0.265 versus -0.064), beta-defensin (-65,025.443 versus -7553.961), and PI3 (-14.005 versus -1.360) expression. Reductions in serum biomarker expression occurred in a dose- and time-dependent manner, with significant reductions from baseline seen with deucravacitinib doses ≥ 3 mg twice daily (P ≤ 0.05). Biomarker expression correlated with disease activity measures such as Psoriasis Area and Severity Index (PASI) at baseline. Biomarker expression also correlated with PASI scores at Week 12.
Conclusion: IL-23/Th17 pathway expression in the serum of patients with psoriasis is an indicator of disease activity and response to deucravacitinib treatment.
Trial Registration Number: NCT02931838.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480296 | PMC |
| http://dx.doi.org/10.1007/s13555-024-01262-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive factors for responders to deucravacitinib treatment in patients with psoriasis.
J Dermatol
December 2024
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib.
View Article and Find Full Text PDFDeucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis.
Autoimmun Rev
December 2024
Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, 41 Mária Street, Budapest 1085, Hungary; Centre for Translational Medicine, Semmelweis University, 22 Baross Street, Budapest 1085, Hungary. Electronic address:
Background: Novel therapies for cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) demonstrated efficacy and safety in previous trials. However, data on the comparison of these treatments is still lacking, limiting their integration into clinical practice. Therefore, our aim is to perform a systematic review and network meta-analysis to compare the efficacy and safety of novel systemic therapies in CLE.
View Article and Find Full Text PDFArticle Synopsis
- - Deucravacitinib is a new oral medication approved in Japan for treating different types of psoriasis, including plaque, generalized pustular, and erythrodermic psoriasis.
- - The POETYK PSO-4 clinical trial involving 74 Japanese patients showed that the drug was effective and well tolerated, with significant improvements in psoriasis symptoms and quality of life over 52 weeks.
- - Results indicated that about two-thirds of patients achieved a Dermatology Life Quality Index score of 0 or 1 by week 52, although the small number of participants with generalized pustular or erythrodermic psoriasis makes it harder to draw broad conclusions for these types.
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials.
JAMA Dermatol
November 2024
Oregon Medical Research Center, Portland, Oregon.
Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed.
Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in the randomized POETYK PSO-1, PSO-2, and nonrandomized long-term extension (LTE) trials.
Design, Setting, And Participants: PSO-1/PSO-2 were global, 52-week, randomized, double-blinded phase 3 trials in patients with moderate to severe plaque psoriasis.
A Case of Extensive Lichen Planus Treated With Deucravacitinib.
Cureus
October 2024
Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA.
Article Synopsis
- * A case was reported of a 52-year-old woman with extensive LP covering 80% of her body, which improved significantly to 20% after two months of treatment with the JAK inhibitor deucravacitinib.
- * Deucravacitinib uniquely targets a specific part of the immune response (tyrosine kinase 2), providing a potentially safer and more effective long-term treatment alternative for chronic skin conditions like LP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!